RoyaltyStat Blog

RoyaltyStat Keyword Search

Posted by Małgorzata Brożyna on Jul 7, 2016 6:34:17 AM

Many search queries entered in the RoyaltyStat search form contain only one keyword or a short phrase such as injection, inject*, mold*, form*, utility*, wireless equipment. One keyword or one phrase search queries are combined with the use of simple operators AND, OR, AND NOT to join the initial keywords.  E.g. inject* OR mold* OR form* in a single query. Initially, users enter a prototypical word of a category or, simply, a word or phrase they know. They don’t develop their search strategies further and don't appear to use our search guide. This behavior is known as a paradox of the active user.

Profit Margin with Heterogeneous Variance

Posted by Ednaldo Silva on Jun 23, 2016 8:24:25 AM

In transfer pricing, we may encounter a situation in which the statistical residuals among the selected comparables do not have a common variance. This phenomenon is called heteroskedascity. To correct this problem, we can transform or deflate the relevant variables and measure them as ratios. E.g., suppose that we have comparable company coordinated pairs of data on sales (S) and “net” (operating) profits (P), and their bivariate scatter diagram suggests a linear relationship:

Gross Profit Methods are Unreliable

Posted by Ednaldo Silva on Jun 14, 2016 5:59:10 AM

If an enterprise makes or buys goods to sell, the cost of goods sold (COGS) can be deducted from net receipts. However, to determine COGS, the inventory at the beginning and end of each tax year must be valued. Consider the symbols:

Profit Margin Using a Power Function

Posted by Ednaldo Silva on May 24, 2016 5:18:06 AM

Linear Profit Function

The typical OECD TNMM (CPM in the U.S.) prescribes a linear statistical function to test the arm's length character of “net” profits (Y) in terms of the net sales (X):

      (1)     Yi = α Xi considering i = 1, 2, …, N comparables

where α is the estimated “net” profit margin. For simplification, we set aside a random error term that is added to equation (1). The controlled taxpayer ("tested party") is the case N + 1.

Non-Linear Profit Function 

Instead of equation (1), "net" profits and sales may be represented by a power function:

     (2)     Yi = α Xiβ

Power functions are pervasive in economic estimates. Equation (2) states that Yi is proportional to Xiβ . In this case, the profit margin is the slope coefficient of equation (2), which below we show is different from α. A power function is appropriate e.g. when the selection of comparables to the tested party includes small and large companies or when the residual variance is not constant.

Profit Margin of Corporate Innovators & Imitators

Posted by Ednaldo Silva on May 15, 2016 7:41:56 PM

Consider the profit margin of selected comparables in the general case when the industry includes two types of uncontrolled (or consolidated) enterprises: (i) innovators that can earn a temporary or persistent excess profit margin, and (ii) imitators that are attracted by the excess profit but whose entry in the industry have the effect of eroding the excess profit margin. As a result, the industry of the controlled taxpayer may exhibit over an audit cycle both a common (or equilibrium) and disequilibrium profit margins earned by innovators and their predators. Here is a schema of this competitive technological and marketing treadmill:

IRS International Practice Units

Posted by Ednaldo Silva on May 7, 2016 2:57:23 PM

The U.S. Internal Revenue Service (IRS) publishes training materials developed by its International Practice Units (IPUs). On March 7, 2016, the IRS released a new publication about the residual profit split method (RPSM). This IPU provides guidance about how the IRS examiners determine if the RPSM is the “best method” under Section 482, and how to apply such method between a U.S. parent and its controlled foreign affiliates when intangible property is transferred.

Selection of the PLI - Profit Margin

Posted by Ednaldo Silva on May 2, 2016 12:30:35 PM

Quartiles of the profit margin are much abused in transfer pricing. Typically, the profit margin (expressed as profits divided by sales) is computed without information about its logical underpinnings. A source of the problem is equivocal regulatory guidance. Another source is the prevailing use of “best practice” sans cogito. In the OECD Transfer Pricing Guidelines, ¶ 2.90, “A net profit indicator of net profit divided by sales, or net profit margin, is frequently used to determine the arm’s length price of purchases from an associated enterprise for resale to independent customers.” A similar postulate is found in the U.S. Treas. Reg. § 1.482-5(b)(4)(ii)(A)(Profit level indicators) in which the profit margin is defined as the “ratio of operating profit to sales”.

It's time to examine the logical foundations of the selected PLI (profit level indicator) because the profit margin defined as a simple ratio of (gross, operating or net) profits to sales may be valid only under special circumstances. Although this same malady applies to other profit indicators that are defined as a fixed proportion to costs or assets, here we concentrate of the profit margin under the OECD TNMM, which is equivalent to the U.S. CPM (comparable profits method).

Valuation of Intangibles - Pfizer Example

Posted by Ednaldo Silva on Apr 23, 2016 3:12:14 PM

Estimates of unidentifiable intangibles based on Tobin’s Q tend to be exaggerated because (in addition to dividend yield) they include a speculative element represented by stock price appreciation. In many cases, capital appreciation can swarm dividend yield. Let’s consider Pfizer Inc. (NYSE: PFE), as an example. Pfizer is a global biopharmaceutical company engaged in discovering, developing and manufacturing healthcare products. Pfizer’s technology and marketing intangible-based products include Prevnar, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, and Xyntha. Several products in Pfizer’s current portfolio were acquired from Wyeth Pharmaceuticals, including Prevnar and Enbrel. Here are some of Pfizer’s selected annual financials for the 12-month ending 2015-12-31 in Million USD. To keep matters in perspective, we provide more information than is needed to value Pfizer's self-created intangibles:

Royalty Rates for Utility Patents

Posted by Ednaldo Silva on Apr 12, 2016 1:57:39 PM

The number of utility patents per license agreement primarily from two high-tech industries shows that most utility patent agreements include one patent number. The number of utility patents per agreement is a hyperbola. It's revealing that the interquartile range of royalty rates does not vary much considering the changing number of patents per agreement. In fact, the median royalty rate is stable at 5%, irrespective of the number of patents per agreement. This suggests that in addition to a stable median royalty rate,

Valuation of Intangibles - Measuring Excess Returns

Posted by Ednaldo Silva on Apr 10, 2016 1:21:34 PM

To measure excess returns attributed to intangibles, we divide the “return on assets” into two components, including a return to tangible assets that is “separate and distinct” from a return to intangible assets. We think of tangible assets consisting primarily of property, plant and equipment, net of accumulated depreciation, and intangible assets consisting of a weighted sum of past investments in R&D, software, and advertising. As such, we define total assets composed of these two components, tangibles (index = 1) and intangibles (index = 2):